Metabolic & Liver Regeneration Program — Stem Cell Therapy Istanbul

Stem cell therapy program targeting metabolic and liver conditions at StemCell Longevita Istanbul. MSC treatments help repair damaged liver tissue, improve insulin sensitivity, restore kidney function, and support metabolic health. Conditions treated include diabetes, liver cirrhosis, fatty liver disease, hepatitis, and chronic kidney disease.

Program Overview

Our Metabolic & Liver Regeneration Program targets the growing epidemic of metabolic disease — from diabetes and fatty liver to chronic kidney disease. Using the regenerative and anti-fibrotic properties of Wharton's jelly MSCs, we aim to restore organ function, reduce fibrosis, and improve metabolic control.

Prof. Dr. Erdal Karaöz's research has specifically explored MSC applications in liver regeneration and metabolic disorders. Combined with 14+ years of clinical practice, our GMP-certified protocols and JCI-accredited hospital setting provide the highest standards of care for complex metabolic conditions.

Program at a Glance

• Expected Stay: 4–6 days in Istanbul
• Treatment Sessions: 2–3 MSC infusion sessions
• Follow-Up Program: Video consultations at 1, 3, 6, and 12 months
• Protocol: Wharton's jelly MSCs via IV + hepatic artery (when indicated)
• Starting From: €8,950 all-inclusive

Your Treatment Journey

1. Metabolic Profiling: Complete metabolic panel (HbA1c, fasting glucose, insulin), liver function tests (ALT, AST, GGT), renal function panel (eGFR, creatinine), FibroScan review, and body composition analysis.
2. Clinical Assessment in Istanbul: Hepatologist/endocrinologist consultation at Liv Hospital, advanced imaging (CT/MRI if required), liver fibrosis staging confirmation, and treatment protocol finalisation.
3. Regenerative Cell Therapy: GMP-certified MSC preparation, IV infusion (200–300M cells), hepatic artery infusion for advanced liver disease (when indicated), and post-infusion metabolic panel.
4. Metabolic Optimisation: Personalised metabolic nutrition plan, blood sugar management, liver-supportive diet, exercise prescription, and medication adjustment planning with your physician.
5. Long-Term Monitoring: Repeat metabolic panels and organ function tests, HbA1c and liver enzyme tracking, imaging follow-up when indicated, and second treatment cycle assessment.

Treatment Protocols

• Systemic IV MSC Infusion: 200–300 million Wharton's jelly MSCs delivered intravenously, providing systemic anti-inflammatory and metabolic regulatory effects. MSCs home to damaged organs and secrete regenerative factors.
• Targeted Hepatic Delivery: For advanced liver fibrosis or cirrhosis, MSCs are delivered directly to the liver via hepatic artery catheterisation, maximising cell concentration at the site of damage.
• Anti-Fibrotic Action: MSCs actively support recovery from fibrosis by suppressing hepatic stellate cell activation and promoting breakdown of excess collagen.
• Metabolic Reprogramming: MSC therapy improves insulin sensitivity, promotes beta-cell regeneration in diabetic patients, and restores hepatocyte function in liver disease.

Conditions Treated

Frequently Asked Questions

Can stem cells help support liver recovery from fibrosis?

Clinical evidence shows MSCs have significant anti-fibrotic properties. They suppress the activation of hepatic stellate cells (the primary drivers of fibrosis) and promote the degradation of excess collagen. Many patients show improvement in FibroScan scores and liver function tests within 3–6 months.

Is this program suitable for Type 1 or Type 2 diabetes?

Our program addresses both types. For Type 2, MSCs improve insulin sensitivity and may help reduce medication dependence. For Type 1, MSCs modulate the autoimmune attack on beta cells and may support residual beta-cell function. Individual assessment determines the optimal protocol.

What about patients with kidney disease?

MSC therapy shows promise for slowing chronic kidney disease progression by reducing renal fibrosis and inflammation. Our program includes comprehensive renal function monitoring and coordination with your nephrologist for medication adjustments.

How does the hepatic artery delivery work?

Hepatic artery infusion is a minimally invasive procedure performed under imaging guidance. A catheter delivers MSCs directly to the liver through the hepatic artery, ensuring maximum cell concentration at the target organ. It is performed at Liv Hospital by experienced interventional radiologists.